Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial | Zendy

Ron T. Gansevoort | Zendy; Esther Meijer | Zendy; Arlene B. Chapman | Zendy; Frank S. Czerwiec | Zendy; Olivier Devuyst | Zendy; Jared J. Grantham | Zendy; Eiji Higashihara | Zendy; Holly B. Krasa | Zendy; John Ouyang | Zendy; Ronald D. Perrone | Zendy; Vicente E. Torres | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial

Author(s) -

Ron T. Gansevoort,

Esther Meijer,

Arlene B. Chapman,

Frank S. Czerwiec,

Olivier Devuyst,

Jared J. Grantham,

Eiji Higashihara,

Holly B. Krasa,

John Ouyang,

Ronald D. Perrone,

Vicente E. Torres

Publication year - 2015

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfv422

Subject(s) - medicine , tolvaptan , autosomal dominant polycystic kidney disease , albuminuria , urology , renal function , placebo , creatinine , post hoc analysis , blood pressure , kidney disease , kidney , pathology , heart failure , alternative medicine

The TEMPO 3:4 Trial results suggested that tolvaptan had no effect compared with placebo on albuminuria in autosomal-dominant polycystic kidney disease (ADPKD) patients. However, the use of categorical 'albuminuria events' may have resulted in a loss of sensitivity to detect changes. The aim of this study is to investigate the effects of tolvaptan on albuminuria as a continuous variable.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research